



## Ziopharm Oncology Presentation at the Jefferies 2019 Global Healthcare Conference to be Webcast

May 23, 2019

BOSTON, May 23, 2019 (GLOBE NEWSWIRE) -- [Ziopharm Oncology](http://www.ziopharm.com), Inc. (Nasdaq:Ziop), a clinical stage immuno-oncology company developing next generation cell and gene therapies, today announced that Laurence Cooper, M.D., Ph.D., CEO of Ziopharm, is scheduled to participate in a webcast session at the Jefferies 2019 Global Healthcare Conference in New York on June 6, 2019 at 10:00 a.m. Eastern Time.

To access the live webcast or the subsequent archived recording, visit the "Investors" section of the Ziopharm website at [www.ziopharm.com](http://www.ziopharm.com). The webcast will be recorded and available for replay on the Company's website for 14 days.

### **About Ziopharm Oncology, Inc.**

Ziopharm Oncology is an immuno-oncology company focused on developing end-to-end cost-effective solutions using its non-viral *Sleeping Beauty* platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled interleukin 12 (IL-12). The *Sleeping Beauty* platform genetically modifies T cells with DNA plasmids to express T-cell receptors (TCRs) to target specific antigens in solid tumors and chimeric antigen receptors (CARs) to target CD19 in blood cancers with the Company's 3rd generation T-cell manufacturing process, rapid personalized manufacture (RPM). The *Sleeping Beauty* platform is being advanced in collaboration with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Eden BioCell. The Company also is developing its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex, as monotherapy and in combination with immune checkpoint inhibitors to treat brain cancer, including in collaboration with Regeneron Pharmaceuticals.

### Company Contact:

Chris Taylor

VP, Investor Relations and Corporate Communications

617-502-1881

[ctaylor@ziopharm.com](mailto:ctaylor@ziopharm.com)



Source: ZIOPHARM Oncology Inc